GT Biopharma (GTBP) Short Interest Ratio & Short Volume

Short interest is the volume of GT Biopharma shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 38,700 shares of GTBP short. 1.74% of GT Biopharma's shares are currently sold short. Learn More on GT Biopharma's current short interest.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of GT Biopharma: DekaBank Deutsche Girozentrale. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.74% of GT Biopharma's floating shares are currently sold short.

GT Biopharma saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 38,700 shares, a decline of 23.5% from the previous total of 50,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

GT Biopharma currently has issued a total of 2,536,000 shares. Some of GT Biopharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. GT Biopharma currently has a public float of 2,230,000 shares.

1.74% of GT Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to GT Biopharma: ALX Oncology Holdings Inc. (17.78%), Pulmatrix, Inc. (0.65%), ABVC BioPharma, Inc. (2.18%), Mannatech, Incorporated (0.78%), KALA BIO, Inc. (7.62%), Longeveron Inc. (4.50%), Annovis Bio, Inc. (13.70%), Sol-Gel Technologies Ltd. (1.80%), Elevation Oncology, Inc. (6.95%), BioVie Inc. (5.76%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks.

Short selling GTBP is an investing strategy that aims to generate trading profit from GT Biopharma as its price is falling. GTBP shares are trading up $0.60 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for GT Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GTBP, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GTBP, twice per month. The most recent reporting period available is April, 30 2025.